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parameters of the computer model were LV axis-ratio, EDV, and percent 
LDMFS. We compared predictions of the model to currently available ciinicel 
data in patients followed 5 years after DCM 
Months 6 12 24 36 48 60 
Actual SV 33.5 37.8 36.4 39.3 35.0 34,0 
Predicted SV 34.5 36.0 35.5 38.9 39.0 40,5 
The above data used a mean LDMFS of 15%. To achieve an augmented 
SV of 50-70 cc, LDMFS must be 20--25%, respectively. Clinically, despite 
significant reductions in NYHA functional class scores, concomitant improve- 
ments in objective parameters are not seen. The computer model explains 
this discrepancy. At an LDMFS of 15% or less, the muscle wrap under- 
goes contraction with increase in LDM tension, and predominantly provides 
structural support to the dilated, failing LV. 
Thus, we conclude that to achieve significant hemodynamic augmentation, 
in addition to NYHA functional class improvement after DCM in patients with 
dilated cardiomyopathy, an LDMFS of 20°/o or more must be attained. 
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~-~'~ Reduction of Ischemlc Deviation and Regional ST 
Wall Motion Oysfunction During PTCA of the Left 
Anterior Descending Coronary Artery (LAO) With 
Synchron ized  Coronary  S inus  Retroper fus ion (SRP) 
Alexander Popov, David M. Lasorda, Christopher A. Nlenaber, C.R. Talbert, 
Kirk U Parr, Mitchell W. Krucoff, Eliot Corday, Bryan C. Donohue. Allegheny 
Generel Hospital, Pittsburgh, PA: Cedars-Sinai Medical Center, Los 
Angeles, CA 
To determine the efficacy of SRP in reducing myocardial ischemia associated 
with PTCA, 120 patients (105--  with LAD lesions) undergoing elective PTCA 
were cannulated for SRP. Two randomly assigned PTCA balloon inflations 
- -  with and without SRP - -  were performed for each patient. ECG results 
were presented in ST segment deviation, and echo results were given a 
regional wall motion score 0NMS) defined ~,s Normal (0), Hypokinesia (1), 
Akinesia (2) and Dyskinesia (3). 
Results. 92 patients completed the protocol. The coronary sinus catheteri- 
zation success rate was 85%, with a mean time to enter the coronary sinus of 
12.7 ~ 14.4 minutes. Complications: 2 cases of pedcardial effusion, treated 
with pedcardiocentesis. In 63 patients with LAD lesions who developed is- 
chemia (at least 1 mm ST change, 1 unit of WMS change or 5% ejection 
fraction (EF) change from baseline) WMS dudng SRP supported PTCA vs 
control was 1.54 ± 1.34 units vs 2.49 ± 1,39 units (P < 0.0001). The EF 
decrease from baseline was subsequently -9.0:1: 4.'P/o vs -13.2 ± 5.7% (P 
< 0.001 ). The mean ECG ST deviation for all ischemic LAD patients was 2.61 
:t: 2.73 mm with SRP vs 4.15 • 3.71 without it (p < 0.001). For 21 of these 
patients, with a mean coronary sinus pressure (CSP) above 25 mmHg, the 
ST deviation was 2.06:1:1,83 mm vs 4.59 ± 4.30 (P < 0.002). Conclusion. 
SRP support reduces the development of myocardial ischemia dunng LAD 
angioplasty, with an enhanced reduction in patients with CSP > 25 mmHg. 
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(7~'~ The Combination o1 Pulmonary Hypertension and 
Right Ventricular Failure Limits Left Ventricular 
Assist Device Pedormance. An Experimental Study 
Ferdinand R. Waldenberger, Bart Meyns, Wiflem Flemeng. Centrum 68 
experimentele Heelkunde n Anaesfhesiofogie, Kathofieke Universiteit 
Leuven, Leuven, Belgium 
Mschanica; and hemndynamic interactions of the heart-lung-unif have been 
accused to strongly influence the performance of a left ventdcular assist 
device (LVAD). In order to investigate this interaction, we designed an exper- 
imental study in anesthetized, open chest animals, 
We performed the study in 55 dogs divided in control group (n = 5) end 5 
groups with mechanical cimulatory support (each n = 10). As assist device 
we used a pneumatic system, the Medos ® HIA-VAD ~ with its pediatric sizes 
(10-ml and 25-ml). In the control group, we induced left ventricular failure 
(LVF) with subsequent occlusions of LAD and CX followed by reperfusion. 
In the next group we supported with an LVAD dudng 90 minutes, starting 
5 minutes after CX occlusion (group II). In the next group, we added right 
ventdcular ischernla by occluding the RCA simultaneously to the CX (group 
III). Those two groups we repeated but with pre-existing acute pulmonary 
hypertension (PHT), induced by the injection of 100 pm glass beads (groups 
IV and V). Group VI was similar to group V (tell and dght ventricular failure 
and PHT), but instead ol a LVAD we used BVAD support. 
In I and V no animal survived the second repodusion period (4 hourS). In fl 
and til (no PHT), all dogs survived in stable conditions. In IV (LVF, PHT), 60% 
survived, In VI with BVAD, only 40=,o survived. In III and V, dudeg occlusion of 
the RCA, the right ventdde stopped contracting and right atrial pressure and 
mean pulmonary pressure equalized. This lead to a significant drop in inflow 
on the left heart side, which still provided sufficient LVAD performance in case 
of absent PHT (111) and lead to death due to "low LVAD output" syndrome 
in V. This "low LVAO Output" syndrome couk:l be partly overcome by BVAD 
support. 
We conclude that RVF and PHT signilicantly influErce LVAD performance 
and can eventually lead to "low LVAD output" syndrome, 
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~ Reduced Serum Paraoxonass Activity Is Associated 
With Progression of Atherosclerosls and New 
Clinical Events: Be~flbrate Coronary 
Atherosclerr, sls Intervention Trial 
Jan Regn~trum, Jan Nilsson, Poter Yhtp, Bojen Cercek, Ulf de Felre, 
CarI-Goran Ericson, Sanjay Kaul, Andem Hamsten, Pred]man K. Shah. 
Cedars-Sinai Medical Center, Los Angeles, CA: Karuliaska Institute, 
Stockholm, SweCen 
Paraoxonase is ;)n antioxidant enzyme carded by a subfraction of HDL- 
cholesterol and may contn'but~ to antlat1~erogenic effec~ of HDL. To deter- 
mine whether parasxonase levels are related to progression of atheresclere- 
sis and clinical coronary events, serum p.~raoxonase activity and quantitative 
corur~ry angiographic findings were cemp~red at baseline and after 5 years 
in 81 patients, age < 45 years, who had an acute myccmdiel infarction and 
were randomized to bezafibrate or plec~oo. As the paraoxonase levels were 
similar in the placebo and bezafibrale treated patients at baseline (356 vs 
359 U/L) and at 5 year follow-up (378 vs 399 U/L) the groups were pooled 
for analysis: 
Median Serum Paraoxonaea (U/L) 
Baseline 5 year's 
New Clinical Events: Yes(N = 10) 273 258 
No (N=71) 356* 399" 
New Occlusion: Yes(N = 20) 329 344 
No (N =61) 356" 410" 
New Lesions: YeslN = 74) 352 375 
No (N = 7) 456 507" 
Ho(:lges Lehman test: 95% CI < 0, Yes vs No Group 
Conclusions: Reduced serum paraoxonase activity in patients with new 
cardiac events or angiegraphic evidence of atherosclerosis progression sup- 
ports an antiatherogenic rote of paraoxonese. 
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~ ' ~  Results of  the Mibefradi l  Ischemla Suppress ion  THai 
(MIST) 
Dan Tzivoni, Shimon Braun, Addanus Scbefliog, isaac Kobrin for the MIST 
Investigators. Shaare Zedek Med. Center, Jerusalem, Israel 
Mibefradii (Mib) is a new once daily benzimidazolyl tetraline calcium an- 
tagonist with negative chronotmpic and no negative lenotropio effects. Its 
antiischemic effect was assessed in 303 patients (20 centers in 7 ceuntdes) 
with proven coronary disease and positive (chest pain and 1 mm ST de- 
pression) exercise test (ET). Exercise and silent ischemia were evaluated by 
repeated El' and 48 hour ambulatory ECG monitoring (AEM). After wash-out 
Baseline Treatment P vs placebo 
ET.~me to STt (s) 
Placebo N = 62 
Mib 25/50 mg N=60 
Mib 50/100 mg N = 60 
Mib 100/150 m0 N=62 
Am 5/10 mg N=59 
Ischem~c episodes (48 h AEM) 
Placebo N = 30 
Mib 20/50 mg N = 35 
Mib 50/100 mg N = 34 
Mib 100/150 mg N = 34 
Am 5/10 mg N=38 
261 299 - 
268 355 0.006 
246 357 < 0.001 
263 385 < 0.001 
264 318 0.136 
5.8 5.2 - 
4.7 2-B 0.069 
5.4 1.7 < 0.001 
6.1 1.3 < 0.001 
4.5 2.3 < 0.036 
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and placebo periods, patients were randomized into 5 groups for 3 weeks: 
placebo, Mib 25/50 rag, 501100 rag, 100/150 mg or amlodipine (Am) 5/10 mg. 
In addition, ET duration and duration of daily silent ischemia improved 
significantly only by Mib 50/100 and 100/150 rag. Both Mib and Am were well 
tolerated. 
Conclusion: Mibefradil given once daily is a highly effective in suppressing 
exercise and daily ischemia, 
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~ T h e  of  Exercise Capacity in the Importance 
Interpretation o f  an Ischeml¢ Response to Exercise 
Testing 
John R Murphy, Michael G. Kahn, Ronald J. Krone. MMIR Group 
Washington Univereily School of Medicine, St. Louis, MO 
We sought o determine the influence of exercise capacity on risk stratification 
in patients with positive exercise thallium tests. The pdmary trial (Muificentar 
Myocardial Ischemia Research Group) of 936 patients with stable coronary 
artery disease who had exercise thallium testing and were followed for 23 
months has already been reported. We stratified patients by beth ECG 
results and exercise capacity, and baseline variables were compared among 
groups. Kaplan-Malar event curves were calculated for the primary outcome, 
the combination of unstable angina, myocardial infarction, or cardiac death. 
For event cuwes for patients stratified by ECG results and stage three, p 
= 0.0004. For patients stratified by overall thallium result and stage 3, p 
= 0.0083. Seen below, the combination of both a positive test and limited 
exercise capacity predicts inoreesed risk. 
Event rate, ECG 1 yr 2 yr Event rate, Thallium I yr 2 Yr 
Positive, < $3 23°/. 33% Positive. < S3 20% 28% 
Positive, ~ $3 9% 13% Positive, > $3 11% 19% 
Negative, < $3 11% 16% Negative, < $3 10% 17% 
Negative, >_ $3 14% 19% Negative, > $3 13% 17% 
Event rates for patients with a positive ECG or thallium test but able to 
reach stage 3 are not different from those of patients with negative ECG 
and thallium tests, Thus, preserved exercise capacity identifies patients at 
low dsk for cardiac events despite an ischercio response to exercise thallium 
testing. 
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~'~- - ]  Cost Implications for Treatment of Cardiac 
Ischemla: An Ancil lary AsymptomaticCardlac 
Isehemla Pilot (ACIP) Study 
Cad J. Pepine, Daniel Mark, Martial Bourassa, Bemard Chairman, 
Geneil Knatterud, Sandra Forman, Craig Pratt, George Bopko, C. 
Richard Conti. Universily of Florida, Gainesville, FL 
Economic implications for ischemia management were studied in 558 pts 
randomized to one of three initial treatment strategies (aegina-guided in = 
183] or Ischemia-gulded (n= 183] medical care or revasculadzation i  = 192]). 
Cost data for events and procedure-related hospitalizations were assigned 
using Medicare diagnosis-related-group (DRG) reimbursement rates in 1993 
dollars, As expected, resource consumption for the initial yr of care was 
considerably higher with revascularization ($13,030) compared with angina- 
and Ischemie-gutded medical strate@es ($4,265 and $4,692/pt enrolled). 
There were significantly more nonprotocol revescuierization procedures and 
events in the medical strategies compared with revascularization, so cost/pt 
for the last 6 rags of the first yre care was greater for the medical strategies 
($1,314 and $2,074) than ravasoularization ($204). If these costs differences 
can be extrapolated through future follow-up yrs then the costs of medical 
strategies could reasWexceeq costs of revasoularization in 4 to 6 yre because 
of the expense of additional events in the medical strategies. 
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Thus revesculadzation may prove, with additional follow-up, to be cost 
effective or even cost saving relative to an initial medical strategy to manage 
ischemla. 
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~ - ~  Combination Therapy With Metoprolo l  and 
Nifedipine Doesn't Have Addit ive AntHschemic 
Effect in individual Patients With Stable Angina 
Pectoris 
Stefano Savonitto, Diego Ardissir,o, Kenneth Egstrup, Inger Wahlqvist, 
Piera A. Madini, Nina Rehnqvist. Milan, Italy for the IMAGE study group 
It is not dear whether combined therapy with metoprolol (M) (which reduces 
oxygen consumption) and nlfediplne (N) (which increases coronary flow) has 
an additive effect in 10Is with stable angina. In a double blind trial 280 pts 
were enrolled in 25 European Centers. After a 2-week placebo (PI) (wk 0), 
10ts were randomtsod to M 200 mg o.d. or N 20 mg b.Ld. for 6 wks; then, they 
randomly added PI or the altsmative drag for a further 4 wks. Exercise tests 
were performed at wks 0, 6 and 10. 248 patients completed the study. At wk 
6, M increased time to -1 mm ST depression (TST) by 70" (95% CI 47 to 
92") in comparison with wk 0, and N by 43" (16 to 69) (both p < 0.01 vs wk 
0; p < 0.05 M vs N). At wk 10, those pts adding PI did not change their mean 
exercise tolerance further, while those adding N to M had a further increase 
(p < 0.05 vs PI) to achieve a gain of 108" (71 to 145") from wk 0, and those 
adding M to N achieved a gain of 107" (64 to 151 ") from wk 0 (p < 0.C5 vs PI). 
However, this mean additive effect of combined therapy was not due to an 
additive effect in individual pts. In fact, only 6% of the pts in the M + N group 
and 6% in the N + M group increased TaT >_ 15% of their basaline value 
both dudng monotherapy anddudng combined therapy, vs 6% in the M ÷ PI 
group and 3% in the N + PI group (all p = ns). Moat of the additive effect in 
the combination groups was due to a "recruitment" of responders (increase 
in TaT > 15°/@ from the value at wk 6) by the 2nd drug when the 1st had 
been ineffective: 10% with M + N, 25% with N + M (p < 0.05 vs N + PI), 12°/@ 
with M + PI and 10% with N + PI. Thus, in a group of pts with stable angina, 
combined therapy with M and N improves exercise tolerance compared with 
monotherapy. However, this effect is not due to an additive effect in individual 
lOtS, but to a "recruitment" of tots non responders to monotherapy. 
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~"6"~"[  Randomized Trial o f  AnUdepreesants In Patients 
With lachemlc Heart Disease 
Mitchell S. Finkal, Andrew Gaffney, Pouzia Laghfissi-Thode, Bruce 
G. Pollock, John Kennedy, Craig Nelson, Ivan Gergel, James R McCaffedy, 
Stevon R Roo~;e. Univemity of Pittsburgh, Pittsburgh, PAl Vanderbilt 
University, Nashville, TN 
Clinical depression following myocardial infarction has recently been identi- 
fied as an independent risk factor for subsequent cardiac death. The Cardiac 
Arrhythmia Suppression Trial raised serious concerns about the use of tri- 
cyclic antidepressants 0"CA) in patients with ischemic heart disease (IHD) 
in view of their Class IA antiarrhythmio properties. Little systematic data are 
available on the cardiac effects of selective serotonin reuptaKe inhlbifore 
($SRI). Accordingly, we conducted the first prospective, randomized, clinical 
trial of the safety and efficacy of the SSRI, Paroxetlne (Px), and the TCA, 
Norldptyline (Nt), in IHD. 41 IHO patients received Px and 40 Nt for treat- 
ment of clinical depression based on a Hamilton Depression Scale (HAM-O) 
score of > 17. Over 80% of the patients in both groups were taking cardiac 
medications including beta blockers and espldn. Antidepressant efficacy was 
similar in both groups with 73% of Nt and 66% of Px patients achieving > 
50% reduction in HAM-D over the 6 week study period. Supine pulse rates 
increased from 70:1= 2 to 78 ± 2 in Nt patients with no ch~.nge in Px patients 
(66 ± 2 vs. 66 a- 1). 37/41 Px and 26/40 Nt completed week 6. 8/40 Nt and 
2/41 Px were withdrawn due to adverse events, including 7 Nt cardiac events 
despite optimal blood levels (unstable angina, dysrhythmie) end 1 Px with 
palpitations. We conclude that depressed patients with IHD can be effectively 
treated with either Nt or Px. However, Px appears to be better tolerated with 
fewer adverse cardiac effects in IHD. 
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{"7~'- 1 -~ Natural History of  Hypertrophic Cardlomyopathy 
During Childhood Revisited in an Unselectsd 
Community-Based Populat ion 
David A. Burton, Liviu C. Pollac, Barry J. Maron. Children's Heart Clinic and 
Minneapolis Heart Institute Foundation, Minneapolis, MN 
Clinical course of hypertrophic cardiomyopathy (HCM) in childhood has been 
